Amitkumar Mehta, MD, discusses overall response rates from the CITADEL-205 study looking at parsaclisib for patients with relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta, MD, associate professor of medicine – hematology & oncology and director of the Lymphoma Working Group at the University of Alabama Birmingham School of Medicine, spoke with CancerNetwork® at the 2021 American Society of Hematology Annual Meeting about response results in patients with relapsed/refractory mantle cell lymphoma (MCL) who were treated with parsaclisib from the phase 2 CITADEL-205 study (NCT03235544).
Mehta said that patients in the daily dosing group, where enrollment continues, experienced an overall response rate of over 70%.
If you look at the overall response rate in all patients, it was 68.5% with a complete response rate of 18%. But importantly, as I mentioned in the daily dosing group, which is the one [where] we continue enrollment, that overall response rate was 70.1% [with a] complete response rate of 16%. Most of the patients had response in their first assessment, which was within 8 weeks of the beginning of treatment. About 96% of patients had regression of that target lesion. If you look at the duration of response, the median duration of response in the daily dosing group was about a year and the median progression-free survival was about 13.6 months. At the follow-up when we presented the data cut-off, the overall response rate was not reached in those patient populations.
Mehta A, Trněný M, Walewski J, et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor: Primary analysis from a phase 2 study (CITADEL-205). Blood. 2021;138(Supplement 1):382. doi: https://doi.org/10.1182/blood-2021-147867